News 
Market Data 
Discover
Replies to post #2352 on Q BioMed Inc (QBIO)
02/14/23 12:02 AM
1303 Notice of Allowance [R-07.2015]
37 CFR 1.311 Notice of Allowance.
(a) If, on examination, it appears that the applicant is entitled to a patent under the law, a notice of allowance will be sent to the applicant at the correspondence address indicated in § 1.33. The notice of allowance shall specify a sum constituting the issue fee and any required publication fee (§ 1.211(e)) which issue fee and any required publication fee must both be paid within three months from the date of mailing of the notice of allowance to avoid abandonment of the application. This three-month period is not extendable.
(b) An authorization to charge the issue fee or other post-allowance fees set forth in § 1.18 to a deposit account may be filed in an individual application only after mailing of the notice of allowance. The submission of either of the following after the mailing of a notice of allowance will operate as a request to charge the correct issue fee or any publication fee due to any deposit account identified in a previously filed authorization to charge such fees:
(1) An incorrect issue fee or publication fee; or
(2) A fee transmittal form (or letter) for payment of issue fee or publication fee.
A Notice of Allowance is prepared and mailed, and the mailing date appearing thereon is recorded in the image file wrapper table of contents.
If an application is subject to publication under 37 CFR 1.211, the Notice of Allowance will require both the issue fee and the publication fee. See 37 CFR 1.211(e). It is noted that the publication fee was reset to $0.00 effective January 1, 2014. See Setting and Adjusting Patent Fees (78 FR 4212, Jan. 18,2013). A "Notice of Allowance and Fee(s) Due." (PTOL-85) will be mailed to the correspondence address of record. The form includes the amount of any required publication fee, as provided in 37 CFR 1.211(e) and 1.311. The form includes an indication that the publication fee is due, if the application was subject to publication and the publication fee has not already been paid. Part B of the form (PTOL-85B) must be returned to the Office with the payment of the issue fee. Applicants are reminded to transmit an extra copy of the PTOL-85B when payment of the issue fee is by way of authorization to debit a Deposit Account. See MPEP § 509.01.
For more information about eighteen month publication and publication fees, visit the USPTO Internet web site at www.uspto.gov.
For applications filed on or after September 16, 2012, if an application is in condition for allowance but does not include an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor, the Office will issue a "Notice of Allowance and Fee(s) Due" (PTOL-85) together with a "Notice of Allowability" (PTOL-37) including a "Notice Requiring Inventor’s Oath or Declaration" (PTOL-2306) requiring the applicant to file an oath or declaration in compliance with 37 CFR 1.63, or substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor, no later than the date of payment of the issue fee to avoid abandonment. If applicant receives a "Notice Requiring Inventor’s Oath or Declaration" and fails to file a proper reply to the notice before or with the payment of the issue fee, the application will be regarded as abandoned. See 37 CFR 1.53(f)(3) (ii).
https://www.uspto.gov/web/offices/pac/mpep/s1303.html
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
Fri, February 10, 2023 at 5:00?AM PST·4 min read
Uttroside B Has Shown Promising Results in Initial Pre-Clinical Testing
NEW YORK, Feb. 10, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA.
The America Cancer Society (www.cancer.org) reported in this year alone, an estimated 42,000 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,000 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space.
Q BioMed announced in 2021 that it has received Orphan Drug Status from the FDA. Q BioMed Inc. is prosecuting patents in multiple jurisdictions and has received patents from Canada, Korea and Japan and has now received notice of an allowable patent in the USA. The Patent is titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC)". Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
The global liver cancer drug market size was valued at US$824 Million in 2020 and is anticipated to grow at a CAGR of 29.4% during forecast period 2021 to 2030. In early pre-clinical investigation Q BioMed's Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs.
